Physician

Christopher David Braden, D.O.

According to 2025 Medicare claims, Christopher Braden, D.O. (NPI: 1497835680) practices hematology/oncology in the San Antonio-New Braunfels, TX market, with the plurality of this provider's patient population coming from Comal, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 78130-3162.

Braden's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 672 traditional Medicare patients, billed 146,583 HCPCS/CPT codes, and received $1,546,703 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,050 prescription claims across 181 beneficiaries totaling $2,177,820 in drug costs, led by Revlimid (Lenalidomide). 2021 DME data shows 11 claims. Open Payments data shows 1 records totaling $20. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $110,637 to $1,546,703. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $859,080 and ending at $2,177,820. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	512	1,678	$110,637
2016	551	1,544	$80,214
2017	562	1,652	$86,260
2018	609	1,971	$101,025
2019	669	1,934	$104,598
2020	696	1,994	$109,370
2021	613	1,740	$116,377
2022	429	6,992	$103,627
2023	683	115,608	$1,703,153
2024	672	146,583	$1,546,703

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	217	1,531	$859,080
2016	224	1,484	$1,333,952
2017	229	1,516	$1,484,537
2018	263	1,610	$2,152,113
2019	297	1,617	$2,109,299
2020	350	2,191	$2,328,597
2021	365	2,492	$3,845,379
2022	251	1,200	$2,063,349
2023	116	529	$648,923
2024	181	1,050	$2,177,820

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	41	$3,761
2016	N/R	24	$3,721
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	11	24	$931
2020	N/R	85	$11,976
2021	N/R	11	$1,081
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	93	231	$95
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	335	867	$63
80053	Blood test, comprehensive group of blood chemicals	284	789	$10
36415	Insertion of needle into vein for collection of blood sample	301	955	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	301	899	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	30	798	$490,395
Xtandi	Enzalutamide	28	840	$394,408
Promacta	Eltrombopag Olamine	21	750	$334,977
Brukinsa	Zanubrutinib	15	450	$207,685
Nubeqa	Darolutamide	13	390	$180,581

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$20	Celgene Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Christopher David Braden, D.O.?

Tedicare shows public-source Medicare data for Christopher David Braden, D.O. (NPI 1497835680), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Christopher David Braden, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Christopher David Braden, D.O.?

Christopher David Braden, D.O. is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Christopher David Braden, D.O. have Open Payments data?

Christopher David Braden, D.O. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.